This is a summary of the European public assessment report (EPAR) for Vizamyl. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Vizamyl. For practical information about using Vizamyl, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
This medicinal product is for diagnostic use only. Vizamyl is a radiopharmaceutical medicinal product indicated for Positron Emission Tomography (PET) imaging of ? amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Vizamyl should be used in conjunction with a clinical evaluation. A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD.
Therapeutic Area (MeSH)
ATC Code
V09AX04
ATC Item
N/A
Pharmacotherapeutic Group
Diagnostic radiopharmaceuticals
Active Substance (Summary)
INN / Common Names
EMA Name
Vizamyl
Medicine Name
Vizamyl
Aliases
N/ANo risk management plan link.
